Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 14Fallopian Tube Neoplasms 13Carcinoma, Ovarian Epithelial 7Prostatic Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Genital Neoplasms, Male 1Esophageal Neoplasms 1

Interventions

Specimen Handling 6Paclitaxel 6Magnetic Resonance Spectroscopy 5Nivolumab 4Carboplatin 4Biopsy 4pembrolizumab 2olaparib 2ceralasertib 2Taxes 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pamiparib 1durvalumab 1cobimetinib 1cediranib 1cabozantinib 1belinostat 1atezolizumab 1X-Rays 1Tissue Banks 1TIC10 compound 1Ipilimumab 1Immunoglobulin G 1Ifosfamide 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × rucaparib × Gynecologic × Clear all
NCT04171700 2023-10-02

LODESTAR

pharmaand GmbH

Phase 2 Terminated
83 enrolled 16 charts
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡